{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:26:29Z","timestamp":1761456389914,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["252300420097"],"award-info":[{"award-number":["252300420097"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018551","name":"Science and Technology Innovation Talents in Universities of Henan Province","doi-asserted-by":"publisher","award":["23HASTIT045"],"award-info":[{"award-number":["23HASTIT045"]}],"id":[{"id":"10.13039\/501100018551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274151","82074063"],"award-info":[{"award-number":["82274151","82074063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117339","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:41:32Z","timestamp":1757745692000},"page":"117339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["The regulatory roles of ppar\u03b1 on hepatic drug-metabolizing enzymes in primary sclerosing cholangitis Syrian hamsters"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0330","authenticated-orcid":false,"given":"Shuaibing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2025.117339_b0005","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0010","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bcp.2025.117339_b0020","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.bcp.2025.117339_b0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.106.013243","article-title":"Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation","volume":"35","author":"Senekeo-Effenberger","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0035","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1210\/en.2005-1132","article-title":"Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression","volume":"147","author":"Patsouris","year":"2006","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.bcp.2025.117339_b0040","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/hq1101.098228","article-title":"Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression","volume":"21","author":"Post","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/mol.112.082503","article-title":"Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPAR\u03b1)","volume":"83","author":"Thomas","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.bcp.2025.117339_b0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1124\/dmd.108.024190","volume":"37","author":"Buckley","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.bcp.2025.117339_b0055","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bcp.2025.117339_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109775","article-title":"Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions","volume":"352","author":"Liu","year":"2022","journal-title":"Chem Biol Interact"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0065","first-page":"589","article-title":"Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method","volume":"42","author":"Gao","year":"2007","journal-title":"Yao Xue Xue Bao"},{"issue":"12","key":"10.1016\/j.bcp.2025.117339_b0070","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1745-7254.2008.00908.x","article-title":"Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/00498250802638155","article-title":"Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design","volume":"39","author":"Perloff","year":"2009","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.bcp.2025.117339_b0080","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"18","key":"10.1016\/j.bcp.2025.117339_b0085","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/rcm.2110","article-title":"High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Kim","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"10.1016\/j.bcp.2025.117339_b0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/aps.2016.10","article-title":"An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s","volume":"37","author":"Chen","year":"2016","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes","volume":"45","author":"Eagling","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.bcp.2025.117339_b0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s002280000252","article-title":"Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6","volume":"56","author":"Ito","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.bcp.2025.117339_b0105","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/rcm.7030","article-title":"Screening of six UGT enzyme activities in human liver microsomes using liquid chromatography\/triple quadrupole mass spectrometry","volume":"28","author":"Joo","year":"2014","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"10.1016\/j.bcp.2025.117339_b0110","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1194\/jlr.M033423","article-title":"Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -\/- mice versus hamsters","volume":"54","author":"Gard\u00e8s","year":"2013","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0925-4439(02)00157-6","article-title":"Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver","volume":"1588","author":"Matsuzaki","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbadis.2017.11.022","article-title":"The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters","volume":"1864","author":"van Golen","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.bcp.2025.117339_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: Functional and Clinical Considerations","volume":"8","author":"Daly","year":"2017","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1081\/DMR-46136","article-title":"Regulation of cytochrome P450 by posttranslational modification","volume":"37","author":"Aguiar","year":"2005","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0135","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1021\/acsinfecdis.9b00012","article-title":"Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis","volume":"5","author":"Tonge","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0009-9236(98)90174-6","article-title":"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-003-0596-0","article-title":"Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers","volume":"59","author":"Peng","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.bcp.2025.117339_b0150","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1124\/dmd.108.023671","article-title":"Interindividual variation in relative CYP1A2\/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes","volume":"36","author":"Zhang","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.clpt.6100149","article-title":"Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam\u2013probes of CYP2C9, CYP1A2, and CYP3A4","volume":"81","author":"Lilja","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hup.2515","article-title":"Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3","volume":"31","author":"Okubo","year":"2016","journal-title":"Hum Psychopharmacol"},{"issue":"12","key":"10.1016\/j.bcp.2025.117339_b0165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","article-title":"Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance","volume":"44","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.bcp.2025.117339_b0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.bcp.2025.117339_b0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0180","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(24)29631-2","article-title":"Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine","volume":"297","author":"Ring","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0185","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.mayocp.2015.03.016","article-title":"Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs","volume":"90","author":"Kaufman","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.bcp.2025.117339_b0190","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bcp.2025.117339_b0195","first-page":"1329","article-title":"The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module","volume":"56","author":"Goodwin","year":"1999","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0200","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/mol.62.2.359","article-title":"Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor","volume":"62","author":"Goodwin","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbi.2005.06.003","article-title":"CAR and PXR: xenosensors of endocrine disrupters?","volume":"155","author":"Kretschmer","year":"2005","journal-title":"Chem Biol Interact"},{"issue":"8","key":"10.1016\/j.bcp.2025.117339_b0210","doi-asserted-by":"crossref","first-page":"e6796","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2025.117339_b0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","article-title":"Glucuronidation: driving factors and their impact on glucuronide disposition","volume":"49","author":"Yang","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.bcp.2025.117339_b0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1021\/mp060020t","article-title":"Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors","volume":"3","author":"Trottier","year":"2006","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.bcp.2025.117339_b0225","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin Lactonization by Uridine 5'-Diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.bcp.2025.117339_b0230","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","article-title":"Pathogenesis of cholestatic liver disease and therapeutic approaches","volume":"139","author":"Hirschfield","year":"2010","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bcp.2025.117339_b0235","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1124\/dmd.112.045112","article-title":"Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPAR\u03b1-, and Nrf2-null mice","volume":"40","author":"Aleksunes","year":"2012","journal-title":"Drug Metab Dispos"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:20:04Z","timestamp":1761456004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"alternative-id":["S0006295225006045"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117339","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The regulatory roles of ppar\u03b1 on hepatic drug-metabolizing enzymes in primary sclerosing cholangitis Syrian hamsters","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117339"}}